title: Effect of lipid-lowering dietary recommendations on the nutritional intake and lipid profiles of chronic peritoneal dialysis and hemodialysis patients.
abstract: Patients with end-stage renal failure are a high-risk group for atherosclerotic cardiovascular disease and commonly have dyslipidemia as a major factor. Dietary manipulation is the recommended first line of therapy for reducing lipid levels in people with normal renal function; however, complex dietary requirements of dialysis-treated patients with end-stage renal failure impose significant constraints. In this study, we evaluated the effect of trying to comply with established lipid-lowering recommendations superimposed on our normally prescribed dialysis diet over 14 weeks in stable subjects treated with either hemodialysis (HD) or chronic peritoneal dialysis (PD). Of 306 dialysis patients screened, 75 subjects were enrolled; 8 subjects did not complete the study. In the remainder, HD subjects (n = 41) decreased saturated fat intakes by 18% overall and cholesterol intakes by 16%. This was associated with a decrease in total cholesterol levels from 232 +/- 8 to 209 +/- 4 mg/dL (mean +/- SEM; P = 0.007) and low-density lipoprotein cholesterol levels from 147 +/- 4 to 131 +/- 4 mg/dL (P = 0.009). However, energy intakes decreased by almost 10%. There were no statistically significant changes in PD patients (n = 26). Only 24.4% of HD (10 of 41 patients) and 15.4% of PD patients (4 of 26 patients) normalized their lipid levels. Considerable problems were encountered in maintaining compliance with the modified dialysis diets. This study shows that if adhered to, properly constructed dialysis diets are close to optimal lipid-lowering recommendations. Further dietary manipulation is difficult, leads to little benefit in the majority, and is accompanied by added problems of adherence. We conclude that the vast majority of dyslipidemic patients with end-stage renal failure require pharmacological therapy.
authors.affiliation: Departments of Renal Medicine, Conjoint Renal Laboratory, Royal Brisbane Hospital, Herston, Australia. saltissid@health.qld.gov.au
authors.forename: D
authors.initials: D
authors.lastname: Saltissi
authors.forename: C
authors.initials: C
authors.lastname: Morgan
authors.forename: B
authors.initials: B
authors.lastname: Knight
authors.forename: W
authors.initials: W
authors.lastname: Chang
authors.forename: R
authors.initials: R
authors.lastname: Rigby
authors.forename: J
authors.initials: J
authors.lastname: Westhuyzen
mesh_terms: D015992:Body Mass Index; D050260:Carbohydrate Metabolism; D004041:Dietary Fats / Q000008:administration & dosage*; D002149:Energy Intake / Q000187:drug effects*; D005223:Fats / Q000378:metabolism; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000178:diet therapy / Q000628:therapy; D007676:Kidney Failure, Chronic / Q000178:diet therapy* / Q000628:therapy; D050356:Lipid Metabolism; D008297:Male; D008875:Middle Aged; D010352:Patient Dropouts; D010530:Peritoneal Dialysis; D011506:Proteins / Q000187:drug effects / Q000378:metabolism; D006435:Renal Dialysis; D016896:Treatment Outcome
chemical_list: D004041:Dietary Fats; D005223:Fats; D011506:Proteins